Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955273 | 0.81 | HSD17B1 (0.45) | MEN1KMT2A | |
| SCHEMBL4867372 | 0.81 | MAP4K4 (0.47) | RAB9AMEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL1900288 | 0.81 | BACE1 (0.41) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL2897272 | 0.81 | IDO1 (0.41) | KDRRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL209262 | 0.80 | MAPT (0.42) | KDRALDH1A1 | |
| SCHEMBL17028871 | 0.78 | IDO1 (0.46) | RAB9AALDH1A1ATMMAPK1 | |
| SCHEMBL500354 | 0.77 | DYRK1A (0.47) | RAB9AMEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL1895969 | 0.74 | APP (0.52) | RAB9AMEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL5257962 | 0.72 | CYP11B2 (0.37) | RAB9AALDH1A1ATMNFKB1NFKB2 | |
| SCHEMBL2753459 | 0.72 | FGFR1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181138-A1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | THE ROCKEFELLER UNIVERSITY (US) | 2020-06-11 | — | — | US | claimed |
| US-20200109167-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2020-04-09 | — | — | US | claimed |
| EP-3601245-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents of The University of Michigan (US) | 2020-02-05 | — | — | EP | claimed |
| EP-3481814-A1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | The Rockefeller University (US) | 2019-05-15 | — | — | EP | claimed |
| WO-2018183411-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-10-04 | — | — | WO | claimed |
| WO-2018009501-A1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | THE ROCKEFELLER UNIVERSITY (US) | 2018-01-11 | — | — | WO | claimed |
| EP-2612861-B1 | FLUORINATED THIAZOLES FOR USE IN TREATING CANCER | UNIV BARCELONA (ES) | 2015-05-13 | — | — | EP | claimed |
| US-8680126-B2 | Fluorinated thiazoles for use in treating cancer | UNIVERSITAT DE BARCELONA (ES) | 2014-03-25 | — | — | US | claimed |
| US-8586550-B2 | Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2013-11-19 | — | — | US | claimed |
| US-20130190367-A1 | FLUORINATED THIAZOLES FOR USE IN TREATING CANCER | UNIVERSITAT DE BARCELONA (ES) | 2013-07-25 | — | — | US | claimed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | claimed |
| WO-2006067589-A1 | MACROLIDES | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | claimed |
| JP-2006516145-A | — | — | 2006-06-22 | — | — | JP | claimed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | claimed |
| CN-1170813-C | N2 phenylamidine derivatives | �ݶ�ũ������˾ | 2004-10-13 | — | — | CN | claimed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | claimed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | claimed |
| US-6143744-A | Sulfamide-metalloprotease inhibitors | SYNTEX (U.S.A.) INC. (US) | 2000-11-07 | — | — | US | claimed |
| EP-0958287-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | claimed |
| WO-1998032748-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | KDR 547/4885RAB9A 1445/4885MEN1 4347/4885 |
| US-20130190367-A1 | FLUORINATED THIAZOLES FOR USE IN TREATING CANCER | TP53, BAX, BCL2 | KDR 1894/4885RAB9A 3206/4885MEN1 2790/4885 |
| US-20200181138-A1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | ITGAV, ITGB3, ITGA4 | KDR 28/4885RAB9A 1075/4885MEN1 2442/4885 |
| US-20200109167-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | DCUN1D2, CLN6, CAPNS1 | KDR 4144/4885RAB9A 1389/4885MEN1 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.